MedTrace Logo

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

NCT06380816 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2026-05-08

No results posted yet for this study

Summary

This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells.

The four main aims of the clinical trial are to find out:

1. The best dose of UCB4594 that can be given safely to participants in the trial.
2. What the side effects of UCB4594 are and how they can be managed.
3. What happens to UCB4594 inside the body and how it affects cancer cells.
4. Whether UCB4594 can cause cancer to shrink.

Conditions

  • Advanced Solid Tumours
  • Squamous Cell Carcinoma of Head and Neck
  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms
  • Triple Negative Breast Neoplasms
  • Carcinoma, Renal Cell (Clear Cell Only)
  • Esophageal Neoplasms
  • Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)
  • Uterine Cervical Neoplasms
  • Ovarian Neoplasms
  • Pancreatic Neoplasms

Interventions

DRUG

UCB4594

Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).

Sponsors & Collaborators

Principal Investigators

  • Fiona Thistlethwaite, Prof · The Christie NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2029-11-30
Completion
2029-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06380816 on ClinicalTrials.gov